TriSalus Life Sciences Inc TLSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device
-
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
-
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
-
TriSalus Life Sciences Reports Second Quarter 2026 Results
-
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Trading Information
- Previous Close Price
- $3.90
- Day Range
- $3.58–3.90
- 52-Week Range
- $2.20–7.95
- Bid/Ask
- $2.28 / $4.00
- Shares Outstanding
- 61.57M
- Market Cap
- $223.52M
- Volume/Avg
- 253,521 / 268,992
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 102
- Website
- https://www.trisaluslifesci.com
Valuation
|
Metric
|
TLSI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 37.54 |
Price/Sales | 4.44 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TLSI
|
|---|---|
Quick Ratio | 4.72 |
Current Ratio | 5.35 |
Interest Coverage | −4.00 |
Quick Ratio
TLSI
Profitability
|
Metric
|
TLSI
|
|---|---|
Return on Assets (Normalized) | −51.80% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −98.18% |
Return on Assets
TLSI
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|v@^F@j | LOCK|ZbJMf | $181B | |||
| Medtronic PLC
MDT
| LOCK|^df@$<$ | LOCK|mlB@ | $121B | |||
| Stryker Corp
SYK
| LOCK|zm%zm@& | LOCK|BKr | $113B | |||
| Boston Scientific Corp
BSX
| LOCK|?<BD&$> | LOCK|&^Dr | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|rX#fr?k | LOCK|mX>& | $50B | |||
| DexCom Inc
DXCM
| LOCK|r^&>>>x | LOCK|bPcW | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|$G@r@< | LOCK|%> | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|V@ | LOCK|fGH | $25B | |||
| Steris PLC
STE
| LOCK|R<HM?! | LOCK|#Y<s< | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|xK@f&>%! | LOCK|k?v | $18B |
United States